导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.30% | 3031/4773 |
| 近一周 | -1.10% | 1679/5465 |
| 近一月 | -6.31% | 4136/5421 |
| 近一季 | 14.27% | 120/5231 |
| 近半年 | 0.22% | 1342/4920 |
| 近一年 | -16.18% | 3813/4394 |
| 近两年 | 19.40% | 2664/2954 |
| 近三年 | -11.32% | 2047/2253 |
| 成立以来 | 47.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.99% 3482/4961 |
-3.96% 3483/5312 |
- - |
- - |
| 2025 | 5.08% 3015/4813 |
0.72% 1782/3635 |
1.46% 2320/4076 |
20.99% 1883/4524 |
-15.02% 4355/4813 |
| 2024 | -12.44% 2377/3463 |
-11.88% 2447/2808 |
-10.01% 2412/3014 |
22.56% 465/3129 |
-9.90% 2960/3463 |
| 2023 | -13.88% 1566/2656 |
-1.65% 1887/2280 |
-9.51% 2057/2385 |
0.56% 361/2515 |
-3.77% 781/2655 |
| 2022 | -24.52% 1225/2207 |
-15.40% 1039/1919 |
2.33% 1312/2016 |
-19.22% 1762/2113 |
7.93% 280/2208 |
| 2021 | -15.73% 1160/1822 |
-4.11% 850/1255 |
15.33% 228/1330 |
-17.01% 1405/1466 |
-8.18% 1577/1822 |
| 2020 | 58.84% 132/1250 |
3.61% 112/1028 |
29.14% 83/1067 |
5.77% 894/1164 |
12.25% 490/1184 |
| 2019 | 42.34% 215/1092 |
28.48% 308/754 |
-4.24% 424/804 |
7.87% 77/850 |
7.26% 461/918 |
| 2018 | -19.33% 159/834 |
- - |
- - |
- - |
-21.60% 674/691 |
| 2017 | 24.88% 118/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.42% 108/605 |
- - |
- - |
- - |
- - |
| 2015 | 32.05% 73/575 |
- - |
- - |
- - |
- - |
| 2014 | 4.42% 225/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达沪深300医药ETF VS. 长安沪深300非周期A(740101) |